Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies
Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies
Not yet recruiting · NCT07485504 · Registry updated 2026-03-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Not yet recruiting | Phase 1 | 2026-03-20 | NCT07485504 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Tcelltech Inc. | 4 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences) | Tianjin | China | 1 |